Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Inthepezon Aug 18, 2020 7:49pm
161 Views
Post# 31425778

RE:RE:Reverse Split at AGM?

RE:RE:Reverse Split at AGM?Hopefully the run up (and uplift) happens around the FDA approval meeting.

MUGs, technically speaking, can they proceed with phase3 if don’t need get FDA approval? I’m confident they will with Stauffer meeting the requirements of the NSAID division. But, in the off chance, they would have to find another country to proceed like Canada or overseas (EMA meeting)?  quote=MUGMODs]The vote is only a re-approval for authorization to consolidate (as the last one is expiring) and it gives them one year to make it happen.  If they don't consolidate within the year, they will need to vote on it again at the next AGM.

On August 20th, I believe they will get the OK to proceed.

But,

On August 20th, it is highly unlikely that the company will act on that approval.

The actual consolidation will happen in the future when management believes it is the best time to do so.  No idea when that will be but I'd say it likely happens as part of a major run-up in share price.

All in my opinion only.

Hope that helps.[/quote]

<< Previous
Bullboard Posts
Next >>